PMID

Data

Article Title

Organization

The inhibition of human cytomegalovirus (hCMV) protease by hydroxylamine derivatives.

Smithkline Beecham Pharmaceuticals

Design and syntheses of 1,6-naphthalene derivatives as selective HCMV protease inhibitors.

Wyeth Research

Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.

Glaxosmithkline

Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.

Glaxosmithkline

Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.

Glaxosmithkline

Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism.

Smithkline Beecham Pharmaceuticals

Benzothiopyran-4-one based reversible inhibitors of the human cytomegalovirus (HCMV) protease.

Smithkline Beecham Pharmaceuticals

Inhibition of human cytomegalovirus protease N(o) with monocyclic beta-lactams.

Boehringer Ingelheim (Canada)

Design and synthesis of monocyclic beta-lactams as mechanism-based inhibitors of human cytomegalovirus protease.

Glaxo Wellcome Research and Development

Tripeptides with non-code amino acids as potential serine proteases inhibitors.

Medical University of Bialystok

Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors.

Merck Research Laboratories